Quick search:
Content Search
Result Content Research
Result Content Research
1 Mizuho Securities Stick to Their Hold Rating for Amgen Inc By
2 Snowflake aims at financial services with data cloud
3 Some dis-Assembly required as an HBV therapy is discontinued
4 Uttar Pradesh police unearth a Love Jihad syndicate, Sayeed Nizam arrested for raping and converting several Hindu girls by disguising as ‘Tantrik’
5 Analyst Expects Bristol to Settle Over $6 Billion Bet That Didn't Pay Out
6 Panel of 58 officers of Police Service prepared for promotion
7 Bristol Myers Squibb's regulatory missteps on Breyanzi can't all be blamed on COVID: analyst
8 Bristol Myers will likely settle the $6.4B Celgene CVR lawsuit at a discount, analyst says. Here's why
9 How to migrate to Snowflake without getting ‘data drunk’
10 Biogen’s Alzheimer drug gains fade after hospitals balk
11 Is the Street Overestimating Biogen’s Aduhelm’s Potential?
12 Investors, patients await FDA decision on Biogen Alzheimer's drug due Monday
13 Bristol Myers hematology chief Ahmed's out the door amid CAR-T missteps
14 Bristol-Myers likely to settle lawsuit related to Celgene drug CVR, analyst says
15 Gilead, Galapagos halt development of experimental drug, denting research alliance
16 Amgen vows to fight after IRS demands $3.6B in back taxes—and a bigger bill could be on the way
17 Social worker Syed Saleem arrested by Chandrayangutta police
18 Cytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors.
19 The FDA Delayed Its Decision on Biogen’s Alzheimer’s Drug. The Stock Is Up 10%.
20 Cricket Association squads for 2021-22 season announced
21 Reports: BMS Hematology Head Out After Liso-Cel and CVR Failure
22 Bristol Myers hints at some problems with an FDA inspection needed for the liso-cel OK, and the Celgene CVR investors are panicking
23 Bristol-Myers Derivative Is Now Worthless as Key Deadline Passes
24 Coherus, known for biosimilars, nears an immunotherapy battle with big pharma
25 FDA dings Bristol Myers' CAR-T plant. Will it hurt liso-cel's approval prospects—and investors' CVR value?
26 Days ahead of Amgen split, Cytokinetics reads out post-hoc data suggesting heart drug works better in sicker patients — but can the CEO win over skeptics?
27 Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
28 Surprise! Amgen's hot KRAS drug seals early FDA approval, winning a shot against 'undruggable' cancer
29 Big Pharma's Q2 growth, ranked: Regeneron, Pfizer lead the way as sales rebound from pandemic depths
30 Gilead’s Yescarta Shows Significant Improvement in Survival in Follicular Lymphoma
31 Apple, Biogen and Bitcoin
32 Biogen Stock: Why 2021 Isn't Just An Aducanumab Story; Two Catalysts To Watch
33 Mizuho Securities Stick to Their Hold Rating for Biogen By
34 Investors send Bristol Myers' CVR soaring on rekindled hopes for timely CAR-T site inspection
35 Amgen's Otezla faces a hit from Bristol's would-be rival, but safety data will tell the full story
36 Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4
37 Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%
38 BridgeBio Pharma and Helsinn Group Obtain FDA Approval for TRUSELTIQ
39 Biogen Stock: Aduhelm Uptake Slow As Company Addresses Controversy
40 'Hub-and-spoke' biotech BridgeBio scores first FDA approval with Alexion castoff
41 Bristol Myers Squibb Stock Rises After Modest Earnings Beat
42 Amgen Reports Results From Otezla’s Phase 3 Trial For Treatment Of Plaque Psoriasis
43 Biogen’s TECFIDERA Approved In China For Treating Multiple Sclerosis
44 Coherus surges into immuno-oncology with $1.1B Junshi deal
45 Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
46 What's In Store For Biogen Stock If Alzheimer's Drug Aducanumab Nabs FDA Nod?
47 19 bureaucrats get three housing units each in Islamabad under govt schemes
48 Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside
49 Aducanumab: this time it's personal | Evaluate
50 Mizuho Securities Stick to Their Buy Rating for Atara Biotherapeutics By
51 Biogen's Alzheimer's drug aducanumab, if approved, may face extra hurdles, slow sales ramp: analysts
52 Why would Amgen want to buy Alexion? Analysts call hotly rumored takeover unlikely, but seize the moment
53 Monetary policy in Latin America and the Caribbean during COVID-19 | VOX, CEPR Policy Portal
54 Coherus BioSciences, inc (CHRS) Q2 2021 Earnings Call Transcript
55 How Shareholders Missed Out on a Potential $6 Billion in Bristol Myers’ Deal for Celgene
56 Biogen Alzheimer's Drug Fails to Gain FDA Panel's Backing
57 Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea
58 Assembly shares plummet after key HBV therapy readout falls short
59 MSEDCL staffer locked up in Mangalwar Peth
60 Amgen, Inc. (AMGN) CEO Bob Bradway on Q2 2021 Results
61 ICYMI: Week in review, June 7-11, 2021 | 2021-06-14
62 Another delay for Bristol Myers cell therapy as FDA extends review
63 Mizuho Securities Stick to Their Buy Rating for Coherus Biosciences By
64 Decision Time Looms for Biotech’s Riskiest Bet
65 Gilead Stock Dives As Light HIV Drug Sales Lead To Quarterly Miss
66 Mizuho Securities Stick to Their Buy Rating for Cytokinetics By
67 Fast start for coronavirus drug boosts Gilead earnings, but stock sinks on forecast
68 AMN Healthcare Services Q2 21 Earnings Conference Call At 5:00 PM ET
69 Mizuho Expands its Healthcare Equity Research Coverage with
70 Amgen & Cytokinetics' Cardiovascular Drug Disappoints in Phase III
71 Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q2 2021 Results
72 Fate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a Splash
73 Atara Biotherapeutics Inc (ATRA) Q1 2021 Earnings Call Transcript
74 SHP2 shore signal growing clearer with Amgen's Lumakras in port
75 New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
76 Gilead disputes report that its drug flopped in leaked coronavirus trial
77 Biogen Announces 1Q20 Beat, But Aducanumab Update Steals The Show
78 Bristol-Myers Play on 3 Drugs Is a Good Bet, Analyst Says
79 JPMorgan Healthcare Conference: Gilead, Biogen Lead Companies That Need Deals
80 Coronavirus pandemic threatens to delay potentially life-changing new medicines
81 Roche stops giving Huntington's disease drug in closely watched study
82 Citi Boasts Most Rising Stars in Equity Research
83 Four of a family held for murder of 22-year-old youth
84 Syed Sohel Ryan (Bigg Boss Telugu 4) Wiki, Age, Female friend, Spouse, Circle of relatives, Biography & Extra
85 Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
86 FiercePharmaPolitics—Gilead CEO sees COVID-19 changing the drug pricing conversation
87 Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript
88 Innovation on hold during the pandemic? FDA says no with 29 approvals in first half of 2021
89 After Alzheimer's drug shows promise, company to seek FDA approval
90 Biotech stocks fall after FDA Commissioner Scott Gottlieb resigns
91 Amgen Wins Appeals Court Ruling Upholding Patents on Enbrel (3)
92 Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
93 Dreams of Hazara children snuffed out in attack on school
94 What ‘Medicare for All’ would do to the health-care sector
95 The Jihadists' War in Pakistan after the US Withdrawal from Afghanistan: Lessons from Al-Qaeda's Assassination of Benazir Bhutto
96 Did Gilead’s miracle drug work or flop? Analysts aren’t quite sure
97 Biogen Alzheimer's drug success: A big step because almost every dementia trial before it has ended in failure
98 High Court upholds 10-year jail term for Haji Salim in wealth case
99 President Alvi confers awards on officers, soldiers of armed forces
100 Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut